Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369092 | 1.00 | RORC (1.00) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7129256 | 0.92 | RORC (0.85) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7125062 | 0.92 | RORC (0.85) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7120914 | 0.91 | RORC (0.83) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7130609 | 0.91 | RORC (0.84) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7130551 | 0.90 | RORC (0.82) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7128352 | 0.90 | RORC (0.81) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7122936 | 0.89 | RORC (0.80) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL7119681 | 0.89 | RORC (0.79) | RORCSMN1; SMN2KMT2APPARGMAPT | |
| SCHEMBL6097331 | 0.89 | RORC (0.79) | RORCSMN1; SMN2KMT2APPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250006331-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-01-02 | — | — | US | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-11951158-B2 | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-04-09 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| WO-2023034381-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-03-09 | — | — | WO | claimed |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | SERVICIO ANDALUZ DE SALUD (ES) | 2022-05-12 | — | — | US | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| CN-113272294-A | 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer | 雅典学院生物医学研究基金会 | 2021-08-17 | — | — | CN | claimed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | claimed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| US-20060194769-A1 | Small molecules that reduce fungal growth | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| WO-2005077126-A9 | USE OF PPARGAMMA SPECIFIC INHIBITORS AS ANTI-CANCER THERAPEUTICS | BOSTON MEDICAL CT CORP (US) | 2005-10-06 | — | — | WO | claimed |
| WO-2005077126-A2 | USE OF PPARGAMMA SPECIFIC INHIBITORS AS ANTI-CANCER THERAPEUTICS | BOSTON MEDICAL CENTER CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| JP-2002539185-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1161412-A1 | NUCLEAR RECEPTOR ARYLATING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-12-12 | — | — | EP | claimed |
| WO-2000055118-A1 | NUCLEAR RECEPTOR ARYLATING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194769-A1 | Small molecules that reduce fungal growth | ERG28, DPM1, CYP51A1 | RORC 2353/4885SMN1; SMN2 4868/4885KMT2A 3817/4885 |
| US-20250006331-A1 | QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES | STAT1, STAT4, ABCB1 | RORC 601/4885SMN1; SMN2 2471/4885KMT2A 3498/4885 |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | ADH1A, ADH5, ADH1C | RORC 542/4885SMN1; SMN2 4550/4885KMT2A 1365/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | RORC 145/4885SMN1; SMN2 339/4885KMT2A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.